Investigational drug · Phase 2
AZD7760
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Staphylococcus Aureus.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "AZD7760"
First trial start
2024
Dec 30, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AZD7760", any sponsor or status.
Conditions studied
As listed on its trial records.
- Staphylococcus Aureus
Largest trials
Live from ClinicalTrials.gov: studies naming "AZD7760" as an intervention, largest first.
- A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)Pivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT06749457 · 242 participants · Start Dec 30, 2024 · Primary completion Mar 8, 2027
Drug: AZD7760 · For: Staphylococcus Aureus
Sites: Huntsville, Alabama; Chula Vista, California; Glendale, California · 40 sites in all
- A Study to Evaluate the Safety and Pharmacokinetics of AZD7760 in Healthy Japanese AdultsActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT07612813 · 18 participants · Start Jun 29, 2026 · Primary completion Sep 13, 2027
Drug: AZD7760 · For: Staphylococcus Aureus Bloodstream Infection
Sites: Sumida-ku, Japan
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.